9 stories mentioning SHA:600420Updated 11d ago
Every FINWIRES story that references SHA:600420, newest first.
Shanghai Shyndec Pharmaceutical's (SHA:600420) unit, Sinopharm Industrial, received a drug registration certificate from China's National Medical Products Administration for penehyclidine hydrochloride injection, according to a Shanghai bourse filing on Friday.The drug is used as a pre-anesthetic medication and as an emergency treatment of organophosphorus poisoning.
Shanghai Shyndec Pharmaceutical (SHA:600420) subsidiary Sinopharm Industrial obtained a drug registration certificate from China's National Medical Products Administration for its clonazepam injection, according to a Friday filing with the Shanghai bourse.Clonazepam is a psychotropic drug indicated for epilepsy, the filing said.Sales of clonazepam reached 1.7 million yuan in 2025, according to market data cited by the company.
Shanghai Shyndec Pharmaceutical (SHA:600420) subsidiary Jiangsu Weichida Pharmaceutical received marketing application approval from China's National Medical Products Administration for its vonoprazan fumarate active pharmaceutical ingredient.The drug is a potassium-competitive acid blocker mainly used to treat reflux esophagitis and Helicobacter pylori infections. It prevents acid production and upper gastrointestinal mucosal damage, the company said in its filing on Wednesday.
Shanghai Shyndec Pharmaceutical's (SHA:600420) chairman, Xu Jihui, resigned after reaching the statutory retirement age, according to a Shanghai bourse filing on Tuesday.Liu Yong also resigned as the company's president due to work reassignment.Wang Yongli will take over as president after the board of directors approved his appointment.The pharmaceutical company's shares fell 2% at the close.
Shanghai Shyndec Pharmaceutical (SHA:600420) received drug registration certificates from China's National Medical Products Administration for two drugs, according to a Shanghai bourse filing on Friday.The certificates are for the dapagliflozin tablets and acarbose tablets, which are both for the treatment for type 2 diabetes mellitus.The pharmaceutical company's shares fell 3% at the close.
Shanghai Shyndec Pharmaceutical (SHA:600420) obtained drug registration from China's medical products regulator for sodium hyaluronate eye drops.The drug is used to treat corneal and conjunctival epithelial injury, according to a Friday filing with the Shanghai bourse.Shares of the company closed 4% lower Friday.
China's drug regulator approved Shanghai Shyndec Pharmaceutical's (SHA:600420) tafluprost eye drops, according to a Tuesday filing with the Shanghai boures.The drops help lower intraocular pressure in patients with open-angle glaucoma and ocular hypertension.
Shanghai Shyndec Pharmaceutical (SHA:600420) received a drug registration certificate from China's National Medical Products Administration for ibrutinib capsules, according to a Shanghai bourse filing on Friday.The drug is used to treat cancers such as lymphoma and Waldenström Macroglobulinemia.The pharmaceutical company invested 15.6 million yuan into the drug's research and development.
Shanghai Shyndec Pharmaceutical (SHA:600420) forecasts attributable profit to fall 59% to 65% year over year to between 126 million yuan and 148 million yuan in the first quarter, according to a Saturday filing with the Shanghai bourse.The decline is attributable to a rise in protectionism in India and the U.S, domestic antibiotic overcapacity, and declining demand from key customers, among others, the filing said.Shares slid 6% during afternoon trading on Monday.
